LSI Europe

Happitech is at the forefront of heart disease detection, making heart health more accessible and effective for everyone. Their innovative solution uses a smartphone camera to detect atrial fibrillation (AFib), a condition that increases stroke risk fivefold. With over 30% of AFib cases going undetected—impacting more than 14 million people in the EU and 7 million in the US—Happitech’s mission is to address this critical gap. Happitech's CE-registered, Class 2a Medical Device utilizes advanced PPG technology, delivering accurate AFib screening in just 90 seconds, without requiring any additional hardware. Currently, the company monitors over 30,000 AFib patients in hospitals across the UK and the Netherlands. Through strategic partnerships, they’ve reached over 500,000 unique users across 11 countries, supported by 13 clinical studies that validate their approach. Happitech is now embarking on one of the largest cardiac monitoring studies in the Netherlands, aiming to screen over 160,000 patients in collaboration with major medical device companies, pharmaceutical firms, and cardiology associations. With FDA approval on the horizon, the U.S. is the next key market for Happitech, where they plan to expand their impact and bring life-saving technology to even more people. We’re excited to announce that Founder and CEO, Yosef Safi Harb has been selected to present Happitech at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Yosef and learn more about Happitech.

Bloomlife Inc (#LSIAlumni) has successfully raised a $12.2 million Series A funding round led by Kapor Capital and Noshaq and included follow-on investments from existing backers such as RH Capital, 15th Rock Ventures, The Grove Foundation, Stardust Equity, and LeanSquare. Bloomlife is an award-winning women’s health company solving the most significant yet underserved global challenges today in maternal health. The Bloomlife MFM-Pro is a prescription-based wearable device designed to help healthcare providers measure maternal and fetal heart rates in the patient's home or in the clinic. The device non-invasively measures the electrical activity of the body and algorithmically extracts maternal and fetal heart rates via cloud-based processing. Bloomlife’s mission is to improve the health of women and babies globally by eliminating preventable adverse birth outcomes. The company believes there's a role for technology to play in addressing this global maternal health crisis. The company has achieved several additional milestones recently, including: ? Expanded its remote maternal care services to include diabetes management. This effectively doubles their serviceable market. ? Secured reimbursement across 18 payers including both commercial and Medicaid ? Closed two additional commercial partnerships with a leading academic medical center and managed service organization Congratulations to the Bloomlife team on all of your recent success! We're excited to announce that Co-Founder & CEO, Eric Dy has been selected to present Bloomlife at LSI Europe '24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Eric and learn more about Bloomlife.

ANEUVO (#LSIEurope24 Innovator) is developing revolutionary bioelectronic medicine to help restore functional independence, improve quality of life, and create a healthier and more equitable world for people living with chronic diseases and conditions. ANEUVO's flagship device, the ExaStim*?* Stimulation System, is a portable, non-invasive transcutaneous spinal cord stimulation (TSS) system, that delivers targeted and selective spinal cord stimulation to modulate the central nervous system. The initial target indication for the ExaStim Stimulation System is the improvement and restoration of motor function in individuals living with paralysis due to spinal cord injury. ANEUVO has hit many key performance milestones since its inception in 2019, including: ? Received FDA Breakthrough Device Designation for its flagship product, ExaStim, a portable, non-invasive spinal neuromodulation system, designed to treating paralysis due to spinal cord injury. ? Secured a Clinical Study Protocol agreement with the US FDA to generate Level-1 clinical evidence. ? Conducting a large-scale double-blinded, randomized, sham-controlled SCI pivotal study at 14 premier hospitals/centers across the US. This video showcases our SCI pivotal study ? Raised $30M+. Now preparing for Series C raise prior to drive successful, global commercialization efforts. We’re excited to announce that CEO, Yi-Kai Lo has been selected to present Aneuvo at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Yi-Kai and learn more about Aneuvo.

ReVision Implant NV (#LSIEurope24 Innovator) is developing Occular, the first visual prosthesis that works well enough to be a medical breakthrough and a commercial success. It has the potential to be a game-changer for 18 million people worldwide who suffer from incurable blindness. The aim is to create a market comparable to that of the current cochlear implants. Occular is based on cameras and signal processing in an external eyeglass frame and a breakthrough high-resolution brain implant with over 2000 microelectrodes in the visual cortex of the patient. Over the last 3 years, ReVision Implant has hit several important milestones: ? Raised 2.3M in dilutive and non-dilutive funding and is now raising a series A round to fund first-in-human trials. ? Proof of functionality in tests on trained rhesus monkeys ? Electrode lifetime of >10 years (and counting) in accelerated aging tests ? In vivo proof of an extremely limited tissue response of the electrode arrays, 100x better than current clinically used DBS electrodes ? Proof of stability of the electrode position We're excited to announce that Co-Founder and CEO, Frederik Ceyssens has been selected to present at LSI Europe '24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Frederik and learn more about ReVision.

Wellumio (#LSIEurope24 Innovator) is a medical technology company that is reshaping the management of neurological emergencies by making MRI technologies accessible at the point of care. Dedicated to overcoming barriers to timely diagnosis and treatment, Wellumio provides physicians with a versatile solution that reduces delays associated with patient transfers and streamlines imaging diagnostics in time-sensitive situations. With an initial focus on emergency rooms and stroke, Wellumio is paving the way for pre-hospital pathways that can further prevent avoidable harm and costs linked to neurological disability. The company has achieved significant technological and commercial milestones to date, including: ? Proving Axana's capability to detect hyperacute stroke lesions within the crucial 'golden hour', with 100% concordance with clinical MRI results. ? Securing $2.75M in funding led by Outset Ventures, along with $2.95M in non-dilutive grants. ? Forming strategic partnerships with the Australian Stroke Alliance and the International Pre-hospital Stroke Treatment Organization ? Expanding the commercial team with experienced industry experts with over 30 years of experience in the medical imaging industry. We're excited to announce that Co-Founder & CEO, Shieak Tzeng has been selected to present at LSI Europe '24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Shieak and learn more about Wellumio.

TAE Life Sciences (#LSIEurope24 Innovator), a subsidiary of TAE Technologies, is advancing cancer treatment with its Boron Neutron Capture Therapy (BNCT) approach. Leveraging accelerator-based neutron beam technology, the company is addressing the challenges of treating cancers like head and neck, glioblastoma multiforme (GBM), and other solid tumors that have been difficult to manage with conventional therapies. BNCT works by administering a boron-containing compound that selectively accumulates in cancer cells. Once absorbed, a low-dose neutron beam is applied, and when the neutrons interact with the boron atoms, a reaction occurs that releases high-energy alpha particles and lithium ions, which damage the cancer cells from within. What sets TAE Life Sciences apart is their use of accelerator-based neutron beams, which offer a safer, more accessible option than the nuclear reactors historically used in BNCT. This innovation allows hospitals and treatment centers to more easily adopt BNCT, expanding their availability to patients. TAE Life Sciences is working with leading research institutions to further develop and expand the clinical applications of BNCT. Their goal is to make this highly targeted therapy a mainstream option for cancers that remain difficult to treat with traditional methods. By combining precision medicine with innovative radiation therapy, they are opening new possibilities for effective cancer treatment. We’re excited to announce that CEO, Robert Hill has been selected to present TAE Life Sciences at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Rob and learn more about TAE Life Sciences.

Hyalex Orthopaedics Inc.(#LSIEurope24 Innovator) has developed a disruptive synthetic materials platform that mimics the structure and function of native cartilage to help patients suffering from diseased and damaged joints. The company aims to immediately restore damaged joint surfaces in a single straightforward surgery to get patients pain-free and back to their active lifestyles as quickly and reliably as possible. The Hyalex Knee Implant has been designed to address a neglected segment of the population known as the “Cartilage Gap” – patients between age 35 and 65 who have painful knee lesions but are too old to rely on unpredictable regenerative techniques and too young for total joint replacement. The Hyalex Knee Implant has received FDA Breakthrough Designation and FDA IDE approval. Hyalex is currently enrolling patients in knee clinical trials in the US and EU, with clinically significant improvements in patient outcomes being reported at the earliest validated time points in both studies. The Hyalex MTP Implant leverages the same impressive biomimetic technology platform to tackle the massive unmet need in Great Toe arthritis, which is estimated to affect more than 3 million people in the US alone. The MTP Implant is in the final stages of development, with FDA 510(k) submission planned before the end of this year. We’re excited to announce that CEO, Carl Vause has been selected to present Hyalex at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Hyalex has experienced significant momentum over the last 12 months and Carl Vause is looking forward to sharing new data on its major clinical milestones at the event.

Nostics (#LSIEurope24 Innovator) is developing a breakthrough point-of-care diagnostics platform for the detection and identification of pathogens in <15 minutes instead of three days, enabling doctors to treat infections more effectively and rapidly. The diagnostic platform is based on a proprietary technology combining nanophotonics and artificial intelligence. The first application for the company's technology will be the identification of urinary tract infections, with 400M incidences globally each year. Nostics has reached significant milestones, including: ? Raised €10M in dilutive and non-dilutive funding and is now raising Series A ? 5 patents filed to protect various aspects of its technology ? Chief Scientific Officer Rochelle Niemeijer was recently awarded the Young Inventor’s Prize (1st place) of the European Patent Office ? Collaborations established with 5 healthcare institutions to work on real patient samples ? Officially certified as a B corp this year We’re excited to announce that CEO, Jeroen Nieuwenhuis has been selected to present Nostics at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Jeroen and learn more about Nostics.

Modra Pharmaceuticals (#LSIEurope24 Innovator) aims to transform intravenous (IV) taxane chemotherapy by developing oral therapies that are safer, better tolerated, and can be conveniently taken at home in tablet form. Modra’s boosted taxanes are orally administered as tablets. In combination with lower toxicities, this should enable patients to take their treatment at home vs. painful and inconvenient infusions in a hospital for the traditional IV formulation. The avoidance of daycare hospitalization for IV-administration can not only positively impact patient quality of life, but also reduce time away from work, and decrease healthcare costs. The company’s lead product is an oral docetaxel formulation (ModraDoc006) which is combined with the booster drug (ritonavir). The company has completed a Phase II trial with ModraDoc006/r in 1st line treatment of patients with metastatic Castration-Resistant Prostate Cancer (mCRPC). This study has recently been published in the European Journal of Cancer (doi:10.1016/j.ejca.2024.114007). We’re excited to welcome Chief Business Officer Eric van der Putten to LSI Europe ‘24 where he’s been selected to present Modra. Eric will present the further plans for the development of ModraDoc006/r. Join us in Portugal to meet with Eric and learn more about Modra.

OctoVascular (#LSIEurope24 Innovator) is developing an automated coronary anastomotic device, to enable cardiac surgeons to perform bypass surgery in a minimally invasive way. The reloadable, single-patient-use device contains a delivery system and multiple vessel connectors. The vessel connectors are crimped on coronary arteries and grafts with ease of use and in a consistent way to the benefit of patients with regard to reduced hospital stays and faster recovery. OctoVascular has reached significant milestones, including: ? Secured a pivotal license agreement, unlocking two decades of invaluable know-how and proprietary vessel connector technology. ? Since inception, OctoVascular has successfully raised € 900k, which has enabled the company to achieve a critical stage: the development of a working alpha prototype. ? Established a Supervisory Board with respected and seasoned industry leaders: Sjaak Deckers, former CEO of Sapiens (sold to Medtronic) and Onward (IPO in 2021), and Prof. Arie-Pieter Kappetein, former cardiac surgeon and CMO of Medtronic. ? World-renowned key opinion leaders, prof. Sam Balkhy, prof. Bob Kiaii, and Dr. Monica Gianoli, joined OctoVascular to bring this transformative shift in patient care. ? Currently seeking an additional €2 million in funding to propel them to the next stage, finalizing the design of its vessel connector, delivery system, and cartridge. We’re excited to announce that CEO, Mark Vrancken Peeters, MD, PhD, MBI has been selected to present OctoVascular at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Mark and learn more about OctoVascular.